Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Applied DNA Sciences Files Patents for Optical DNA SigNature Markers and Enters the Instant Detection Market.


STONY BROOK Stony Brook may refer to:

Massachusetts:
  • Stony Brook, a tributary of the Charles River in Boston
  • Stony Brook (MBTA station) on the Orange Line in Jamaica Plain
  • Stony Brook (B&M station), a former Boston and Maine Railroad station in Weston
, N.Y. -- Applied DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 Sciences, Inc. (OTC Bulletin Board OTC Bulletin Board

An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system.
: APDN) today announced that it has filed multiple patent applications to cover its latest developments in optical reporter markers. These reporters "announce" the presence of the DNA markers to which they are attached. The development of these reporter adducts enables instantaneous detection of Applied DNA's SigNature[TM] DNA markers by commercially available, hand-held devices. A blinking light, an audible beep or the reading of an invisible 2-D bard code signals detection. The company has begun to demonstrate its new platform to individual customers, and plans a formal unveiling for a later date.

"This is a significant accomplishment for Applied DNA Sciences," stated Dr. James Hayward James Hayward is the pseudonym of James Nice (b. 6 January 1966 in Essex), English writer on military and modern art history. Educated at the University of Glasgow prior to working in publishing and as a solicitor. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The company has been working on the development of a system for remote instant detection for some time and we now have in place a number of proprietary optical markers which can be covalently linked to SigNature[TM] DNA to provide an instant means of detecting the presence of SigNature[TM] DNA by small, hand-held readers. DNA-reporter adducts offer a high-speed first defense that enable a rapid screening to identify the presence of a SigNature[TM] DNA marker. When complemented by our forensic methods, we provide an integrated solution for brand-owners and governments."

While intended as a rapid screen of our SigNature[TM] anti-counterfeit mark, SigNature[TM] Optical Reporters also enhance the logistical value of DNA marks by permitting the co-encryption of the content of a 2D barcode.

"With these discoveries," stated Dr. Benjamin Liang, Chief Science Officer, "the company now offers three levels of detection for its SigNature[TM] DNA, from a simple rapid screen which can be done instantaneously anywhere with a portable handheld device to more definitive forensic tests which can be tested either in the field or at our laboratories. This underscores the significant progress APDN has made in the past two years and it is what we believe many of our potential clients and investors have been waiting for. We now have a highly cost effective and easy to implement solution."

"Rapid Screens" utilizing optical reporters afford APDN and its customers the ability to quickly identify the presence or absence of SigNature[TM] DNA Markers using portable handheld detectors. For more definitive testing, clients can have their SigNature[TM] DNA marked items forensically authenticated au·then·ti·cate  
tr.v. au·then·ti·cat·ed, au·then·ti·cat·ing, au·then·ti·cates
To establish the authenticity of; prove genuine: a specialist who authenticated the antique samovar.
 with services and tools provided by APDN.

Dr. Hayward continued. "If you are serious about brand protection and care about the quality of the products that are being produced and ultimately consumed, we believe that DNA is the only true workable solution in that it provides a unique, unbreakable code, and has the staying power that no other security technology can offer. We believe we are well prepared to provide exactly what is needed in the field so that genuinely branded products can be easily differentiated from counterfeits."

About APDN

Applied DNA Sciences markets and sells DNA encrypted and embedded Inserted into. See embedded system.  solutions that are forensically authenticated by machine readable Data in a form that can be read by the computer, which includes disks, tapes and punch cards. Printed fonts that can be scanned and recognized by the computer are also machine readable.  devices. These solutions can be easily integrated with a range of inks, threads, varnishes, adhesives as well as thermal ribbon, inkjet and laser ink. Applied DNA Sciences' products can help protect the brands and intellectual property that can easily be eroded by counterfeiting counterfeiting, manufacturing spurious coins, paper money, or evidences of governmental obligation (e.g., bonds) in the semblance of the true. There must be sufficient resemblance to the genuine article to deceive a person using ordinary caution. , product diversion and fraud.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-KSB, filed on January 15, 2008 and our subsequent quarterly reports on Form 10-QSB. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008, Gale Group. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 22, 2008
Words:688
Previous Article:Spiceworks Wins AlwaysOn OnMedia Top 100 Award.
Next Article:Accenture Strengthens Technology Outsourcing Capabilities in Canada with Opening of Delivery Center in Mississauga.
Topics:



Related Articles
Random Samples.
Random Samples.
LAWRENCE LIVERMORE FINDS UNIQUE ANTHRAX DNA SIGNATURES.
Applied DNA Sciences introduces DNA-embedded ink technology. (Fresh Ink).
Primagen and University of British Columbia enter mitochondrial DNA licensing agreement detection.
DNA signatures speed detection of Salmonella.
Xenomics' patent applications for the diagnosis and monitoring of infectious diseases published.
New patent suits address groundbreaking techniques.
From the benchtop to the courtroom.
Xenomics announces license with Asuragen for NPM1 leukemia diagnostics.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles